Amylyx develops treatments for neurodegenerative diseases, aiming to improve the lives of patients affected by conditions such as ALS, Alzheimer’s disease, and Wolfram Syndrome. Founded in 2013 by Brown University students, the company places significant emphasis on addressing the root causes of these diseases. Their initial product, RELYVRIO™, secured FDA approval in 2022, marking a pivotal moment in their mission. With a commitment to collaboration and accountability, Amylyx prioritizes values such as curiosity and authenticity in their approach to research and development. Headquartered in Cambridge, MA, and with a growing presence in Europe and Asia-Pacific, Amylyx fosters a culture that encourages talented individuals to join their efforts in transforming the landscape of neurological care.